Profile data is unavailable for this security.
About the company
GSK plc, formerly GlaxoSmithKline PLC is a global healthcare company. The Company is focused to improve the quality of human life by helping people. The Company operates through three core businesses: Pharmaceuticals, Vaccines and Consumer Healthcare. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency viruses (HIV), immuno-inflammation and oncology. It also focuses on immunology, human genetics, and advanced technologies to deliver transformational new medicines for patients. The Company's research and development focuses on developing vaccines against infectious diseases that combine high medical needs and market potential. The Company's Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands for oral health, pain relief, cold, flu and allergy, digestive health, and vitamins, minerals and supplements. It provides prescription medicines, vaccines, and consumer healthcare products.
- Revenue in GBP (TTM)36.48bn
- Net income in GBP5.11bn
- Incorporated1999
- Employees90.10k
- LocationGSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
- Phone+44 208 047 5000
- Fax+44 208 047 7807
- Websitehttps://www.gsk.com/
Mergers & acquisitions
| Acquired company | GSK:LSE since announced | Transaction value |
|---|---|---|
| Affinivax Inc | 1.63% | 3.30bn |
| Sierra Oncology Inc | -1.55% | 2.08bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lonza Group AG | 4.60bn | 573.70m | 32.50bn | 16.22k | 56.67 | 3.90 | 32.84 | 7.06 | 9.05 | 39.54 | 72.61 | 131.42 | 0.3502 | 2.50 | 6.58 | 333,518.30 | 4.38 | 5.00 | 5.36 | 6.14 | 39.01 | 39.82 | 12.52 | 13.97 | 1.88 | 17.42 | 0.1966 | 31.40 | 19.99 | 5.53 | -7.67 | 17.49 | 29.66 | 3.33 |
| GSK plc | 36.48bn | 5.11bn | 89.29bn | 90.10k | 17.39 | 5.52 | 10.24 | 2.45 | 1.01 | 1.01 | 7.20 | 3.18 | 0.4348 | 2.07 | 4.93 | 404,857.00 | 7.16 | 6.96 | 10.85 | 11.61 | 65.29 | 68.48 | 16.46 | 14.68 | 0.9467 | 11.64 | 0.5956 | 94.83 | 0.044 | 4.11 | -23.73 | 36.90 | 4.50 | 0.00 |
| Sanofi SA | 34.72bn | 5.74bn | 109.51bn | 95.44k | 18.97 | -- | 15.33 | 3.15 | 5.30 | 5.30 | 32.15 | -- | -- | -- | -- | 422,686.00 | -- | 5.19 | -- | 6.23 | 69.14 | 68.06 | 16.50 | 15.36 | -- | 31.63 | -- | 66.94 | 4.83 | 2.46 | -49.38 | 7.20 | -0.387 | 2.28 |
| Novo Nordisk A/S | 17.24bn | 5.71bn | 158.47bn | 49.30k | 36.66 | 26.89 | 24.94 | 9.19 | 21.45 | 21.45 | 64.74 | 29.24 | 0.8805 | 1.27 | 4.64 | 3,118,242.00 | 29.15 | 32.65 | 57.87 | 63.12 | 83.38 | 83.79 | 33.11 | 33.52 | 0.693 | 35.93 | 0.2769 | 50.18 | 10.91 | 4.72 | 13.33 | 4.72 | -2.23 | 6.47 |
| AstraZeneca plc | 33.83bn | -866.91m | 166.94bn | 83.10k | -- | 5.63 | 34.21 | 4.93 | -0.5412 | -0.5412 | 22.84 | 19.13 | 0.5023 | 1.91 | 5.54 | 407,146.70 | -1.28 | 2.62 | -1.75 | 3.66 | 72.61 | 78.90 | -2.55 | 6.61 | 0.6606 | 4.97 | 0.461 | 196.26 | 40.58 | 10.22 | -96.50 | -49.76 | -1.01 | 1.03 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 01 May 2022 | 161.81m | 3.18% |
| BlackRock Fund Advisorsas of 03 Mar 2021 | 131.21m | 2.58% |
| Dodge & Coxas of 31 Dec 2021 | 117.97m | 2.32% |
| Norges Bank Investment Managementas of 01 May 2022 | 112.09m | 2.21% |
| Schroder Investment Management Ltd.as of 01 May 2022 | 88.52m | 1.74% |
| Capital Research & Management Co. (Global Investors)as of 01 May 2022 | 76.72m | 1.51% |
| Legal & General Investment Management Ltd.as of 01 May 2022 | 74.32m | 1.46% |
| BlackRock Advisors (UK) Ltd.as of 01 May 2022 | 72.92m | 1.43% |
| Silchester International Investors LLPas of 01 May 2022 | 66.61m | 1.31% |
| Mondrian Investment Partners Ltd.as of 01 May 2022 | 55.96m | 1.10% |
